{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:43:36Z","timestamp":1773297816241,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["01MH90001"],"award-info":[{"award-number":["01MH90001"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.schres.2008.04.023","type":"journal-article","created":{"date-parts":[[2008,6,5]],"date-time":"2008-06-05T08:30:43Z","timestamp":1212654643000},"page":"104-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1"],"prefix":"10.1016","volume":"103","author":[{"given":"Jonathan M.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki G.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry A.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail L.","family":"Daumit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin S.","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Scott","family":"Stroup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2008.04.023_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","author":"American Diabetes Association","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2008.04.023_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2008.04.023_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1017\/S1092852900026298","article-title":"Balancing efficacy and safety in treatment with antipsychotics","volume":"12","author":"Correll","year":"2007","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.schres.2008.04.023_bib4","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.163.9.1077","article-title":"Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease","volume":"163","author":"Eberly","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.schres.2008.04.023_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","article-title":"A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls","volume":"80","author":"Goff","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.schres.2008.04.023_bib6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2008.04.023_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2307\/2530041","article-title":"A review of some statistical methods for covariance analysis of categorical data","volume":"38","author":"Koch","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.schres.2008.04.023_bib8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.schres.2008.04.023_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.schres.2008.04.023_bib10","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.schres.2008.04.023_bib11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","article-title":"Use of metabolic markers to identify overweight individuals who are insulin resistant","volume":"139","author":"McLaughlin","year":"2003","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.schres.2008.04.023_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","article-title":"The effects of antipsychotic therapy on serum lipids: a comprehensive review","volume":"70","author":"Meyer","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.schres.2008.04.023_bib13","doi-asserted-by":"crossref","unstructured":"Meyer, J.M., Davis, V.G., Goff, D.C., McEvoy, J.P., Nasrallah, H.A., Davis, S.M., Rosenheck, R.A., Daumit, G.L., Hsiao, J., Swartz, M.S., Stroup, T.S., Lieberman, J.A., 2008. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia Research 101, 273\u2013286.","DOI":"10.1016\/j.schres.2007.12.487"},{"key":"10.1016\/j.schres.2008.04.023_bib14","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jama.298.15.1794","article-title":"Severe mental illness and risk of cardiovascular disease","volume":"298","author":"Newcomer","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2008.04.023_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996408001989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996408001989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:21:55Z","timestamp":1760296915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996408001989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":15,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0920996408001989"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2008.04.023","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2008.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}